Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission - results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial.
Saved in:
| Title: | Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission - results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial. |
|---|---|
| Authors: | Schmitz A; Department of Haematology, Aalborg University Hospital, Forskningens Hus, Søndre Skovvej 15, DK-9000, Aalborg, Denmark.; Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark., Brøndum RF; Department of Haematology, Aalborg University Hospital, Forskningens Hus, Søndre Skovvej 15, DK-9000, Aalborg, Denmark.; Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark., Johnsen HE; Department of Haematology, Aalborg University Hospital, Forskningens Hus, Søndre Skovvej 15, DK-9000, Aalborg, Denmark.; Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark.; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.; For the Nordic Myeloma Study Group (NMSG)., Mellqvist UH; For the Nordic Myeloma Study Group (NMSG).; South Elvsborg Hospital, Boras, Sweden., Waage A; For the Nordic Myeloma Study Group (NMSG).; Norwegian University of Science and Technology and St. Olav's University Hospital, Trondheim, Norway., Gimsing P; For the Nordic Myeloma Study Group (NMSG).; Department of Haematology, University of Copenhagen, Copenhagen, Denmark., Op Bruinink DH; Department of Immunology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands., van der Velden V; Department of Immunology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands., van der Holt B; Department of Immunology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.; HOVON Data Center, Department of Haematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Hansson M; For the Nordic Myeloma Study Group (NMSG).; Skane University Hospital, Lund, Sweden., Andersen NF; For the Nordic Myeloma Study Group (NMSG).; Department of Haematology, Aarhus University Hospital, Aarhus, Denmark., Frølund UC; For the Nordic Myeloma Study Group (NMSG).; Department of Haematology, Sjællands Universitetshospital, Roskilde, Denmark., Helleberg C; For the Nordic Myeloma Study Group (NMSG).; Department of Hematology, Herlev Hospital, Herlev, Denmark., Schjesvold FH; For the Nordic Myeloma Study Group (NMSG).; Oslo Myeloma Center, Department of Haematology, Oslo University Hospital, Olso, Norway.; KG Jebsen Center for B Cell Malignancies, University of Oslo, Oslo, Norway., Ahlberg L; For the Nordic Myeloma Study Group (NMSG).; Division of Hematology, Linkoping University Hospital, Linkoping, Sweden., Gulbrandsen N; For the Nordic Myeloma Study Group (NMSG).; Oslo Myeloma Center, Department of Haematology, Oslo University Hospital, Olso, Norway.; KG Jebsen Center for B Cell Malignancies, University of Oslo, Oslo, Norway., Andreasson B; For the Nordic Myeloma Study Group (NMSG).; NU Hospital Group, Uddevalla hospital, Uddevalla, Sweden., Lauri B; For the Nordic Myeloma Study Group (NMSG).; Sunderby Hospital, Luleaa, Sweden., Haukas E; For the Nordic Myeloma Study Group (NMSG).; Department of Haematology, Stavanger University Hospital, Stavanger, Norway., Bødker JS; Department of Haematology, Aalborg University Hospital, Forskningens Hus, Søndre Skovvej 15, DK-9000, Aalborg, Denmark.; Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark., Roug AS; Department of Haematology, Aalborg University Hospital, Forskningens Hus, Søndre Skovvej 15, DK-9000, Aalborg, Denmark.; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark., Bøgsted M; Department of Haematology, Aalborg University Hospital, Forskningens Hus, Søndre Skovvej 15, DK-9000, Aalborg, Denmark.; Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark.; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark., Severinsen MT; Department of Haematology, Aalborg University Hospital, Forskningens Hus, Søndre Skovvej 15, DK-9000, Aalborg, Denmark.; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark., Gregersen H; Department of Haematology, Aalborg University Hospital, Forskningens Hus, Søndre Skovvej 15, DK-9000, Aalborg, Denmark.; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.; For the Nordic Myeloma Study Group (NMSG)., Abildgaard N; For the Nordic Myeloma Study Group (NMSG).; Department of Haematology, Odense University Hospital, Odense, Denmark., Sonneveld P; Department of Immunology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.; For the European Myeloma Network (EMN)., Dybkær K; Department of Haematology, Aalborg University Hospital, Forskningens Hus, Søndre Skovvej 15, DK-9000, Aalborg, Denmark. k.dybkaer@rn.dk.; Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark. k.dybkaer@rn.dk.; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark. k.dybkaer@rn.dk. |
| Source: | BMC cancer [BMC Cancer] 2022 Feb 05; Vol. 22 (1), pp. 147. Date of Electronic Publication: 2022 Feb 05. |
| Publication Type: | Evaluation Study; Journal Article |
| Journal Info: | Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1471-2407 |
|---|---|
| DOI: | 10.1186/s12885-022-09184-1 |
